Crizotinib
ALK inhibitor for treatment of non-small-cell lung cancer
Ratings
0
Nobody has rated this yet. Be the first!
Successful crizotinib retreatment after crizotinib-induced interstitial lung disease.
Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.
Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.
Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.
Lists
0